UMMS Affiliation

Massachusetts Biologic Laboratories

Date

10-24-2002

Document Type

Article

Subjects

Adolescent; Adult; Aged; Antibodies, Bacterial; Antibody Formation; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; *Immunization; Male; Middle Aged; Pneumococcal Infections; Pneumococcal Vaccines; Time Factors; *Tissue Donors; Transplantation, Homologous; Vaccines, Conjugate

Disciplines

Medical Cell Biology | Medical Immunology

Abstract

Patients undergoing hematopoietic cell transplantation (HCT) are at increased risk for infections with Streptococcus pneumoniae and have long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines. We examined whether donor immunization with a heptavalent pneumococcal conjugate vaccine (PCV7) would elicit protective antibody responses to additional doses of vaccine administered early after transplantation. Ninety-six patients scheduled to receive an allogeneic hematopoietic cell transplant were randomized with their donors to receive either a dose of PCV7 vaccine or no vaccine before transplantation. All patients received PCV7 at 3 months, 6 months, and 12 months following transplantation, and serotype-specific antibody concentrations were determined after each dose. Following HCT, geometric mean antibody concentrations of patients in the immunized donor group were significantly higher for 5 of the 7 vaccine serotypes after one dose (P <.05) and for 4 of the 7 serotypes after 2 doses of vaccine (P <.03). Sixty-seven percent of patients in the immunized donor group had presumed protective IgG concentrations more than or equal to 0.50 microg/mL to all 7 serotypes following the first dose of vaccine compared to 36% in the unimmunized donor group (P =.05). After the third dose of vaccine, both groups had more than 60% of patients with concentrations at least 0.50 microg/mL to all vaccine serotypes. Donor immunization enhances early antibody responses of patients undergoing HCT to pneumococcal conjugate vaccine. A 3-dose schedule of PCV7 vaccine at 3, 6, and 12 months is immunogenic in these patients regardless of donor immunization.

Rights and Permissions

Citation: Blood. 2003 Feb 1;101(3):831-6. Epub 2002 Sep 19. Link to article on publisher's site

DOI of Published Version

10.1182/blood-2002-03-0832

Related Resources

Link to article in PubMed

Journal Title

Blood

PubMed ID

12393732

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.